KLRS
Kalaris Therapeutics

121
Mkt Cap
$195.63M
Volume
28,335.00
52W High
$12.90
52W Low
$2.14
PE Ratio
-1.41
KLRS Fundamentals
Price
$10.42
Prev Close
$10.46
Open
$10.19
50D MA
$9.40
Beta
0.87
Avg. Volume
76,713.65
EPS (Annual)
-$11.73
P/B
4.67
Rev/Employee
$0.00
$69.91
Loading...
Loading...
News
all
press releases
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold
Wall Street Zen raised Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Srinivas Akkaraju Buys 479,847 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju purchased 479,847 shares of Kalaris Therapeutics stock in a transaction dated Thursday, December 18th. The stock...
MarketBeat·13d ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju acquired 479,847 shares of the stock in a transaction dated Thursday, December 18th. The shares were purchased at...
MarketBeat·13d ago
News Placeholder
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8%
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 867,767 shares, an...
MarketBeat·30d ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen lowered Kalaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·1mo ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat.com reports...
MarketBeat·1mo ago
News Placeholder
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1%
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 503,479...
MarketBeat·2mo ago
News Placeholder
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy
Chardan Capital raised Kalaris Therapeutics to a "strong-buy" rating in a research note on Tuesday...
MarketBeat·2mo ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, MarketBeat.com...
MarketBeat·2mo ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest KLRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.